Package Leaflet: Information for the Patient
Vaborem 1g/1g powder for concentrate for solution for infusion
meropenem/vaborbactam
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is Vaborem
Vaborem is an antibiotic that contains two active substances: meropenem and vaborbactam.
What is Vaborem used for
Vaborem is used in adults to treat certain serious bacterial infections:
It is also used to treat infections:
Vaborem must not be given to you if
Warnings and precautions
Tell your doctor or nurse before you are given Vaborem if:
If any of the above applies to you, or if you are not sure, tell your doctor or nurse before using Vaborem.
You may develop signs and symptoms of severe skin reactions (see section 4). If this happens, tell your doctor or nurse immediately so that they can treat the symptoms.
Tell your doctor or nurse if you get diarrhoea during treatment.
This medicine may affect your liver. Your doctor may take some blood from you to check how your liver is working while you are taking the medicine.
New infection
Although Vaborem can combat certain bacteria, there is a possibility that you may get a different infection caused by another microorganism during or after treatment. Your doctor will closely monitor you to detect any new infection and will give you another treatment if necessary.
Blood tests
If you are going to have any blood tests, tell your doctor that you are taking Vaborem, as you may get an abnormal result with a test called a ‘Coombs test’. The results of this test show the presence of antibodies that can destroy red blood cells or that may be affected by your immune system's response to Vaborem.
Children or adolescents
Vaborem must not be used in children or adolescents under 18 years of age, as it is not known if it is safe to use the medicine in these age groups.
Other medicines and Vaborem
Tell your doctor if you are taking, have recently taken or might take any other medicines.
It is especially important that you tell your doctor if you are taking any of the following medicines:
If any of the above applies to you, tell your doctor before using Vaborem.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
As a precaution, you should not take this medicine during pregnancy.
It is important that you tell your doctor if you are breast-feeding or planning to breast-feed before you are given Vaborem. Small amounts of this medicine may pass into breast milk and may affect your baby. Therefore, you should stop breast-feeding before you start treatment with Vaborem.
Driving and using machines
Vaborem may make you feel dizzy, drowsy or lethargic, may give you a headache or a tingling sensation (pins and needles) or, in rare cases, cause a fit or convulsions. This may affect your ability to drive, use tools or machines.
Vaborem contains sodium
This medicine contains 250 mg of sodium (a major component of cooking/table salt) in each vial. This is equivalent to 12.5% of the maximum recommended daily intake of sodium for an adult.
The recommended dose is 2 vials (a total of 2 g of meropenem and 2 g of vaborbactam), given every 8 hours. Your doctor will decide how many days of treatment you need, depending on the type of infection.
A doctor or nurse will give you Vaborem by infusion (drip) into a vein over 3 hours.
Patients with kidney problems
If you have kidney problems, your doctor may reduce the dose. Your doctor may want to take some blood from you to see how your kidneys are working.
If you are given too much Vaborem
A doctor or nurse will give you Vaborem, so it is unlikely that you will be given too much. If you think you have been given too much Vaborem, tell your doctor or nurse immediately.
If you miss a dose of Vaborem
If you think you have missed a dose, tell your doctor or nurse immediately.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
If you notice any of the following side effects, tell your doctor immediately because you may need urgent medical treatment:
Other side effects
If you notice any of the following side effects, tell your doctor or nurse:
Common:(may affect up to 1 in 10 people)
Uncommon:(may affect up to 1 in 100 people)
Rare:(may affect up to 1 in 1,000 people)
Frequency not known:(cannot be estimated from the available data)
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of the month shown.
Do not store above 25°C.
Vaborem Composition
Product Appearance and Package Contents
Vaborem is a white to light yellow powder for concentrate for solution for infusion, supplied in a vial.
Vaborem is available in packs containing 6 vials.
Marketing Authorization Holder
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare
L-1611, Luxembourg
Luxembourg
Manufacturer
ACS Dobfar, S.p.A.
Nucleo Industriale S. Atto
(loc. S. Nicolo’ a Tordino)
64100 Teramo (TE)
Italy
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: +370 52 691 947 |
България Менарини България ЕООД / Menarini Bulgaria EOOD Тел.: +359 24540950 | Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 |
Česká republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 17997320 |
Danmark Menarini International Operations Luxembourg S.A. Tlf: +352 264976 | Malta Menarini International Operations Luxembourg S.A. Tel: +352 264976 |
Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67070 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | Norge Menarini International Operations Luxembourg S.A. Tlf: +352 264976 |
Ελλάδα MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Österreich
Tel: +43 1 879 95 85-0 |
España Laboratorios Menarini S.A. Tel: +34-93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal
Tel: +351 210 935 500 |
Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821 361 | România Berlin-Chemie A.Menarini S.R.L. Tel: +40 21 232 34 32 |
Ireland
Tel: +353 1 284 6744 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 01 300 2160 |
Ísland Menarini International Operations Luxembourg S.A. Sími: +352 264976 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2 544 30 730 |
Italia
| Suomi/Finland Berlin-Chemie/A.Menarini Suomi OY Puh/Tel: +358 403 000 760 |
Κύπρος MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Sverige Pharmaprim ABTel: +46 8355933 |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103210 | United Kingdom (Northern Ireland)
Tel: +44 (0)1628 856400 |
Date of Last Revision of this Leaflet:07/2023
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu.
------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Vaborem is intended for intravenous (i.v.) administration, only after reconstitution and dilution.
Aseptic techniques must be used for the preparation and administration of the solution.
The number of vials used for a single dose will depend on the patient's creatinine clearance (CrCl).
Reconstitution:
20 ml of 9 mg/ml (0.9%) sodium chloride injection solution should be withdrawn from a 250 ml bag of 9 mg/ml (0.9%) sodium chloride injection solution for each vial and reconstituted with the appropriate number of vials of meropenem/vaborbactam for the corresponding dose of Vaborem:
After careful mixing to dissolve, the reconstituted meropenem/vaborbactam solution will have an approximate concentration of 0.05 g/ml of meropenem and an approximate concentration of 0.05 g/ml of vaborbactam. The final volume is approximately 21.3 ml. The reconstituted solution is not for direct injection. The reconstituted solution must be diluted before intravenous infusion.
Dilution:
To prepare the 2 g/2 g dose of Vaborem for intravenous infusion: immediately after reconstitution of two vials, the entire contents of the reconstituted vial from each of the two vials should be withdrawn and added back to the 250 ml bag of 9 mg/ml (0.9%) sodium chloride injection solution (normal saline). The final concentration of the infusion of meropenem and vaborbactam will be approximately 8 mg/ml each.
To prepare the 1 g/1 g dose of Vaborem for intravenous infusion: immediately after reconstitution of one vial, the entire contents of the reconstituted vial should be withdrawn and added back to the 250 ml bag of 9 mg/ml (0.9%) sodium chloride injection solution (normal saline). The final concentration of the infusion of meropenem and vaborbactam will be approximately 4 mg/ml each.
To prepare the 0.5 g/0.5 g dose of Vaborem for intravenous infusion: immediately after reconstitution of one vial, 10.5 ml of the reconstituted vial contents should be withdrawn and added back to the 250 ml bag of 9 mg/ml (0.9%) sodium chloride injection solution (normal saline). The final concentration of the infusion of meropenem and vaborbactam will be approximately 2 mg/ml each.
The diluted solution should be visually inspected for particles. The color of the diluted solution is clear to light yellow.
After dilution, the infusion should be administered within 4 hours if stored at 25°C, or within 22 hours if refrigerated at 2 – 8°C.
From a microbiological point of view, the product should be used immediately after reconstitution and dilution.
Vaborem is not chemically compatible with solutions containing glucose. This medicinal product must not be mixed with other medicinal products except for those mentioned in section 6.6 of the SmPC.